Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study by Pepper, DJ et al.
Pepper et al. AIDS Res Ther  (2015) 12:35 
DOI 10.1186/s12981-015-0076-5
RESEARCH
Independent predictors of tuberculosis 
mortality in a high HIV prevalence setting: a 
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Abstract 
Background: Identifying those at increased risk of death during TB treatment is a priority in resource-constrained 
settings. We performed this study to determine predictors of mortality during TB treatment.
Methods: We performed a retrospective analysis of a TB surveillance population in a high HIV prevalence area that 
was recorded in ETR.net (Electronic Tuberculosis Register). Adult TB cases initiated TB treatment from 2007 through 
2009 in Khayelitsha, South Africa. Cox proportional hazards models were used to identify risk factors for death (after 
multiple imputations for missing data). Model selection was performed using Akaike’s Information Criterion to obtain 
the most relevant predictors of death.
Results: Of 16,209 adult TB cases, 851 (5.3 %) died during TB treatment. In all TB cases, advancing age, co-infection 
with HIV, a prior history of TB and the presence of both pulmonary and extra-pulmonary TB were independently 
associated with an increasing hazard of death. In HIV-infected TB cases, advancing age and female gender were inde-
pendently associated with an increasing hazard of death. Increasing CD4 counts and antiretroviral treatment during 
TB treatment were protective against death. In HIV-uninfected TB cases, advancing age was independently associated 
with death, whereas smear-positive disease was protective.
Conclusion: We identified several independent predictors of death during TB treatment in resource-constrained 
settings. Our findings inform resource-constrained settings about certain subgroups of TB patients that should be 
targeted to improve mortality during TB treatment.
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Background
Over the past two decades, HIV co-infection has 
emerged as the greatest risk factor for developing active 
TB and causing TB-related deaths [1]. Reducing TB-
related deaths is a priority in high burden countries. One 
of several strategies to reduce TB mortality is to identify 
those at increased risk of death. This strategy is especially 
important in developing countries where incident TB is 
frequent, and access to resources is constrained.
In regions of high TB incidence and high HIV preva-
lence, risk factors for TB case fatality include: older age 
(mostly >35 years) [2–5]; HIV positivity [2, 4, 6–9]; fea-
tures of advanced HIV [8, 10–12]; smear-negative dis-
ease [3, 7, 9, 10, 13]; and malnutrition [4, 8, 14]. Studies 
in South Africa have determined predictors of TB mor-
tality [6, 7, 15, 16]. However, these studies were of small 
or moderate sample size [6, 7, 15, 16], performed in gold 
mines with concomitant silicosis [6] or preceded the 
expansion of HIV services, trimethoprim-sulfamethoxa-
zole chemoprophylaxis and antiretroviral treatment [6, 7, 
15, 16].
Identifying predictors for mortality in South Africa 
in the ART era using TB surveillance data could inform 
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resource allocation and strategies to reduce TB-related 
mortality. Here, we report our analyses of a complete 
electronic TB register of over 16,000 TB cases, where we 
determined predictors of death during TB treatment in a 
high HIV prevalence setting.
Results
Description of TB cases
Over a 36-month period, we recorded 17,735  TB cases. 
After exclusion of TB cases aged less than 16  years, we 
recorded 16,209  TB cases for 15,556 individuals. The 
median age was 33  years (IQR 26–41) and 48  % of TB 
cases were female (Table  1). Of those with known HIV 
status (n = 14,392), 72 % (n = 10,379) were infected with 
HIV and 28  % (n  =  4013) were not. Of those infected 
with HIV, the median CD4 count was 146 cells/μL (IQR 
65–266), 95  % received TMP-SMX chemoprophylaxis 
and 29  % received ART during TB treatment. Median 
duration of follow-up for all TB cases was 168 days (IQR 
163–209). During TB treatment, 5.3 % and 10.5 % of TB 
cases died or were lost to follow-up, respectively. At least 
76 % of TB cases were alive at the end of TB treatment.
Predictors of death
Cumulative mortality according to HIV status is shown 
in Fig. 1. Multivariate regression analyses of all TB cases 
found that independent predictors of death were increas-
ing age, infection with HIV, a prior history of TB, the 
presence of extra-pulmonary TB and the presence of 
both pulmonary and extra-pulmonary TB (Table 2). Gen-
der, smear result and the presence of only extra-pulmo-
nary TB had no significant effect on mortality.
Multivariate regression analyses of HIV-infected TB 
cases found that independent predictors of death were 
increasing age and female gender (Table 3). An increas-
ing CD4 count and ART during TB treatment were pro-
tective against death. Smear result, history of prior TB, 
TMP-SMX prophylaxis during TB treatment and the 
presence of only extra-pulmonary TB had no clear effect 
on mortality.
Multivariate regression analyses of HIV-uninfected TB 
cases found that increasing age was an independent pre-
dictor of death, whereas smear-positive disease was pro-
tective (Table 4). Gender, site of TB disease and history of 
prior TB were not associated with mortality.
Multivariate regression analyses stratified according to 
age found that certain risk factors differed according to 
HIV status (Tables 5, 6, 7). In younger patients (<45 years 
of age), HIV infection and the presence of both pulmo-
nary and extra-pulmonary TB were associated with mor-
tality (all TB patients, Table 5). In younger HIV infected 
patients, higher CD4 counts and initiation of ART dur-
ing TB treatment were associated with reduced mortality 
(Table 6). In younger HIV uninfected patients, a positive 
smear result was protective against mortality (Table 7). In 
older patients (≥45 years), prior TB was associated with 
mortality (all TB patients, Table 5). In older HIV infected 
patients, female gender was associated with increased 
mortality whereas higher CD4 counts and initiation of 
ART during TB treatment were associated with reduced 
mortality (Table  6). Finally, in older HIV uninfected 
patients a positive smear result was protective against 
mortality (Table 7).
Discussion
In a surveillance population of over 16,000 adults with 
active TB, we found several easily identifiable and inde-
pendent predictors of death during TB treatment. In 
those not infected with HIV, the risk of death increased 
with advancing age but decreased with smear-positive 
disease. In those infected with HIV, the risk of death 
increased with advancing age and female gender but 
decreased with a higher CD4 count and ART. These find-
ings inform resource allocation strategies to reduce TB 
mortality in high HIV/TB settings.
Among HIV-infected adults receiving TB treatment, we 
found that women were at an increased hazard of death 
compared to men. This finding is interesting as HIV-
infected men without TB typically have worse outcomes 
on ART, compared to women [27]. This discrepancy sug-
gests that gender-TB or gender-ART interactions exist. 
Unmeasured confounding such as background mor-
tality gender differences in this community could also 
explain this difference. Among HIV-uninfected persons 
with active TB, one study from Bolivia similarly found 
increased mortality among women, while other studies 
from Brazil, Italy, China, and Viet Nam found increased 
mortality among men [28–33].
Only 30  % of HIV-infected TB cases in our study 
received ART during TB treatment. This finding is likely 
because ART was only indicated for those with a CD4 
count of less than 200 cells/μL, according to national 
guidelines at the time [18]. We found that ART reduced 
the risk of dying in our analysis. This finding occurred 
despite possible time-dependent confounding [34], 
wherein the observed benefit of ART would be smaller 
than anticipated because ART was started in sicker 
patients at various time-points during TB treatment. Our 
study adds impetus to current WHO guidelines that ART 
be initiated among all HIV-infected adults with active 
TB, regardless of CD4 count [35]. In those infected with 
HIV, interventions such as starting ART at higher CD4 
counts may need to be prioritized in those of advanced 
age, or of the female gender. In those not infected with 
HIV, interventions will need to be prioritized in those 
with advancing age and those with smear-negative 
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Table 1 Description of TB cases by HIV status
Data shows number of cases (n) and percentage (%) unless otherwise specified
IQR inter-quartile range, TB active tuberculosis, TMP-SMX trimethoprim sulfamethoxazole 160/80 mg chemoprophylaxis
a A total of 15,556 patients experienced 16,209 cases of tuberculosis. The female proportions for these 15,556 patients are: 48.6 % (7552/15,556) of all patients; 34.7 % 
(1347/3886) of HIV uninfected patients; 56.3 % (5584/9923) of HIV infected patients; and 35.6 % (621/1747) of patients with HIV status not recorded
HIV uninfected  
(n = 4013)
HIV infected  
(n = 10,379)
HIV status not recorded  
(n = 1817)
Total 
(n = 16,209)
Sexa
 Data available 4013 (100.00) 10,379 (100.00) 1817 (100.00) 16,209 (100.00)
 Sex female 1380 (34.39) 5798 (55.86) 639 (35.17) 7817 (48.23)
Age
 Data available 4012 (99.98) 10,378 (99.99) 1817 (100.00) 16,207 (99.99)
 Median age (IQR) 32 (23–46) 33 (28–40) 31 (24–43) 33 (26–41)
 <25 1380 (34.4) 1587 (15.29) 578 (31.81) 3545 (21.87)
 25–35 907 (22.61) 4636 (44.67) 538 (29.61) 6081 (37.52)
 35–45 690 (17.2) 2900 (27.94) 333 (18.33) 3923 (24.21)
 45–60 764 (19.04) 1164 (11.22) 278 (15.3) 2206 (13.61)
 >60 271 (6.75) 91 (0.88) 90 (4.95) 452 (2.79)
Anatomic site of TB
 Data available 4013 (100.00) 10,379 (100.00) 1817 (100.00) 16,209 (100.00)
 Pulmonary 3358 (83.68) 6805 (65.57) 1465 (80.63) 11,628 (71.74)
 Extra-pulmonary 543 (13.53) 2726 (26.26) 292 (16.07) 3561 (21.97)
 Both 112 (2.79) 848 (8.17) 60 (3.30) 1020 (6.29)
Duration of TB treatment
 Data available 4013 (100.00) 10,379 (100.00) 1817 (100.00) 16,209 (100.00)
 Median duration (IQR) 168 (164–194) 168 (161–219) 167 (161–187) 168 (163–209)
Retreatment for TB
 Data available 4013 (100.00) 10,379 (100.00) 1817 (100.00) 16,209 (100.00)
 Retreated case 1001 (24.94) 3332 (32.10) 469 (25.81) 4802 (29.63)
TB smear results
 Data available 4013 (100.00) 10,379 (100.00) 1817 (100.00) 16,209 (100.00)
 Smear negative 972 (24.22) 4773 (45.99) 528 (29.06) 6273 (38.70)
 Smear positive 2716 (67.68) 4032 (38.85) 1103 (60.70) 7851 (48.44)
 No smear performed 325 (8.10) 1574 (15.17) 186 (10.24) 2085 (12.86)
Outcome
 Data available 4013 (100.00) 10,379 (100.00) 1817 (100.00) 16,209 (100.00)
 Alive 3237 (80.66) 7813 (75.28) 1333 (73.36) 12,383 (76.40)
 Dead 132 (3.29) 641 (6.18) 78 (4.29) 851 (5.25)
 Lost to follow-up 405 (10.09) 1079 (10.40) 210 (11.56) 1694 (10.45)
 Transferred out 137 (3.41) 493 (4.75) 124 (6.82) 754 (4.65)
 Not known 102 (2.54) 353 (3.40) 72 (3.96) 527 (3.25)
CD4 count
 Data available – 6433 (61.98) – –
 Median CD4 count (IQR) – 146 (65–266) – –
TMP-SMX during TB treatment
 Data available – 10,012 (96.46) – –
 TMP-SMX during TB treatment – 9520 (95.09) – –
ART during TB treatment
 Data available – 8942 (86.15) – –
 ART during TB treatment – 2614 (29.23) – –
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Fig. 1 Kaplan Meier plot showing cumulative mortality during TB treatment: (1) overall mortality, and (2) mortality by HIV status
Table 2 Crude and adjusted hazard ratios with confidence intervals from a Cox model after multiple imputation for all 
deaths during TB treatment
TB tuberculosis, ART antiretroviral treatment, TMP-SMX trimethoprim sulfamethoxazole 160/80 mg chemoprophylaxis, HR  hazard ratio, 95 % CI 95 % confidence 
interval, AIC Akaike information criterion
Crude Adjusted Adjusted (selected by AIC*)
HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI)
Sex female 1.05 (0.91–1.20) 0.51 1.08 (0.94–1.24) 0.28
Age
 <25 Reference Reference Reference
 25–35 1.88 (1.42–2.48) 0.00 1.53 (1.15–2.03) 0.00 1.52 (1.14–2.01)
 35–45 2.37 (1.78–3.14) 0.00 1.93 (1.45–2.58) 0.00 1.90 (1.43–2.53)
 45–60 3.54 (2.66–4.72) 0.00 3.25 (2.42–4.35) 0.00 3.20 (2.40–4.27)
 >60 6.54 (4.65–9.19) 0.00 7.22 (5.11–10.22) 0.00 7.22 (5.11–10.19)
Anatomic site of TB
 Pulmonary Reference Reference Reference
 Extra-pulmonary 1.38 (1.18–1.62) 0.00 1.20 (0.99–1.45) 0.06 1.29 (1.10–1.51)
 Both 1.62 (1.27–2.06) 0.00 1.45 (1.14–1.85) 0.00 1.46 (1.15–1.86)
Prior TB 1.28 (1.11–1.49) 0.00 1.16 (1.00–1.35) 0.05 1.16 (1.00–1.34)
HIV infected 1.82 (1.51–2.20) 0.00 1.94 (1.58–2.40) 0.00 2.00 (1.63–2.46)
TB smear result
 Smear negative Reference Reference
 Smear positive 0.73 (0.63–0.84) 0.00 0.93 (0.79–1.10) 0.41
 No smear performed 1.11 (0.91–1.36) 0.31 1.08 (0.87–1.34) 0.47
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disease. Smear positive disease was protective of death 
among HIV-uninfected TB cases. Patients with smear 
negative disease may have had a diagnosis other than TB. 
Our previous study investigated reasons for clinical dete-
rioration in patients on TB treatment. We found that 4 % 
of HIV infected TB patients and 9 % of HIV uninfected 
TB patients had alternate diagnoses to TB [36]. In HIV 
uninfected TB patients, these diagnoses included post-
TB bronchiectasis, pulmonary silicosis, bacterial sepsis 
and lung cancer [37]. Smear negative disease could also 
reflect alternate illnesses such as sarcoidosis and lym-
phoma where inappropriate therapy could be fatal.
Among those infected with HIV, we found no associa-
tion between smear results and death. Studies have found 
conflicting results with both smear positive and smear 
negative TB disease being associated with death [3, 9, 32]. 
TMP-SMX chemoprophylaxis has been shown to reduce 
mortality in HIV-infected patients [38, 39]. In our study, 
TMP-SMX chemoprophylaxis was not associated with 
reduced mortality. However, we were unable to assess the 
impact of this intervention on mortality because more 
than 95 % of our HIV-infected TB cases received TMP-
SMX chemoprophylaxis.
Our study has several limitations. Loss to follow-up 
occurred in 10.5 % of cases and likely led to under-ascer-
tainment of deaths [40]. Our study is retrospective, so 
our findings may be subject to random error, bias, and 
confounding. We minimized random error by utilizing 
a large surveillance population of over 16,000 TB cases. 
Also, trained health care personnel used a standardized 
data form during the study period, which likely reduced 
bias. Lastly, confounding was minimized by employing 
multivariate regression analyses including variables such 
as age, gender, HIV status, CD4 count if HIV-infected, 
TB smear result at TB diagnosis, history of prior TB, ana-
tomic site of TB, and concurrent TMP-SMX and antiret-
roviral treatment during TB treatment. These variables 
have been shown to affect mortality during TB treat-
ment [41]. We acknowledge that we did not have data 
on variables that may have influenced mortality, such 
Table 3 Crude and adjusted hazard ratios with confidence intervals from a Cox model after multiple imputation for all 
HIV-infected deaths during TB treatment
TB tuberculosis, ART antiretroviral treatment, TMP-SMX trimethoprim sulfamethoxazole 160/80 mg chemoprophylaxis, HR hazard ratio, 95 % CI 95 % confidence 
interval, AIC Akaike information criterion
Crude Adjusted Adjusted (selected by AIC*)
HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI)
Sex female 0.98 (0.85–1.14) 0.84 1.24 (1.06–1.45) 0.01 1.23 (1.06–1.44)
Age
 <25 Reference Reference Reference
 25–35 1.25 (0.92–1.68) 0.15 1.24 (0.92–1.68) 0.17 1.25 (0.92–1.70)
 35–45 1.58 (1.16–2.14) 0.00 1.60 (1.17–2.18) 0.00 1.62 (1.19–2.21)
 45–60 2.39 (1.73–3.29) 0.00 2.50 (1.80–3.46) 0.00 2.54 (1.83–3.52)
 >60 4.72 (2.99–7.44) 0.00 4.79 (3.00–7.65) 0.00 4.80 (3.00–7.66)
Anatomic site of TB
 Pulmonary Reference Reference
 Extra-pulmonary 1.16 (0.98–1.38) 0.09 1.14 (0.93–1.41) 0.21
 Both 1.44 (1.12–1.85) 0.01 1.29 (1.00–1.68) 0.05
Prior TB 1.12 (0.95–1.32) 0.18 1.16 (0.98–1.37) 0.09
TB smear result
 Smear negative Reference Reference
 Smear positive 0.98 (0.83–1.16) 0.83 1.07 (0.89–1.28) 0.47
 No smear performed 1.16 (0.93–1.45) 0.18 1.08 (0.85–1.36) 0.54
CD4 count
 <50 Reference Reference Reference
 50–100 0.79 (0.61–1.02) 0.07 0.79 (0.60–1.02) 0.07 0.78 (0.60–1.01)
 100–200 0.55 (0.41–0.75) 0.00 0.54 (0.40–0.71) 0.00 0.53 (0.40–0.71)
 200–350 0.47 (0.37–0.61) 0.00 0.43 (0.34–0.56) 0.00 0.43 (0.33–0.55)
 350+ 0.28 (0.18–0.43) 0.00 0.24 (0.16–0.37) 0.00 0.24 (0.16–0.37)
TMP-SMX chemoprophylaxis 1.01 (0.69–1.46) 0.96 0.88 (0.60–1.29) 0.52
ART during TB treatment 0.76 (0.64–0.91) 0.00 0.60 (0.50–0.72) 0.00 0.61 (0.51–0.73)
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as AIDS-defining illnesses; non-infective co-morbid ill-
nesses; isoniazid prophylaxis therapy, nutritional factors; 
anemia; baseline performance status; socio-economic 
factors; smoking, alcohol and substance misuse; duration 
of symptoms prior to TB diagnosis; treatment adherence 
and drug-resistant strains; and HIV viral load [41]. We 
also were unable to correlate chest x-ray findings with 
mortality. Mortality during TB treatment may corre-
late with the extent of TB disease as evidenced by chest 
X-ray involvement and the presence or absence of cavity 
formation.
Despite these limitations, our study’s large sample size, 
standardized data collection and careful inputting of 
missing data add value to current literature. Our study 
identifies several easily recognizable factors that could 
be targeted to reduce TB mortality. Firstly, HIV testing 
should be performed for all TB patients. Secondly, we 
recommend a triple strategy among those infected with 
HIV. This triple strategy would include immediate (same 
day) CD4 counts at HIV diagnosis, expedited referral to 
HIV clinics for ART initiation and prioritization of ART 
for those of advancing age and of female gender. In HIV 
infected and HIV uninfected TB patients, our study iden-
tified those with advancing age as an independent risk 
factor for death. By identifying increasing age as a pre-
dictor of death, further research is now needed to deter-
mine whether excess TB deaths are due to age-related 
co-morbid illnesses or due to dysfunctional intracellular 
processes, such as autophagy [42]. Age related co-morbid 
illnesses such as ischemic heart disease, stroke, lower 
respiratory infections, diabetes and chronic obstructive 
pulmonary disease are listed in the top twenty causes 
of death in South Africa [43]. Importantly, a substantial 
Table 4 Crude and adjusted hazard ratios with confidence intervals from a Cox model after multiple imputation for all 
HIV-uninfected deaths during TB treatment
TB tuberculosis, ART antiretroviral treatment, TMP-SMX trimethoprim sulfamethoxazole 160/80 mg chemoprophylaxis, HR hazard ratio, 95 % CI 95 % confidence 
interval, AIC Akaike information criterion
Crude Adjusted Adjusted (selected by AIC*)
HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI)
Sex female 0.80 (0.56–1.15) 0.23 0.83 (0.58–1.19) 0.32
Age, years
 <25 Reference Reference Reference
 25–35 3.01 (1.35–6.68) 0.01 2.84 (1.28–6.30) 0.01 2.91 (1.31–6.45)
 35–45 3.93 (1.73–8.96) 0.00 3.53 (1.55–8.05) 0.00 3.63 (1.59–8.26)
 45–60 9.58 (4.56–20.11) 0.00 7.75 (3.65–16.42) 0.00 7.93 (3.74–16.79)
 >60 20.38 (9.57–43.37) 0.00 16.14 (7.52–34.63) 0.00 16.24 (7.57–34.85)
Anatomic site of TB
Pulmonary Reference Reference
 Extra-pulmonary 2.18 (1.48–3.21) 0.00 1.38 (0.85–2.22) 0.19
 Both 1.48 (0.60–3.66) 0.40 1.23 (0.49–3.06) 0.66
Prior TB 1.94 (1.35–2.78) 0.00 1.41 (0.97–2.04) 0.07 1.39 (0.96–2.01)
TB smear result
 Smear negative Reference Reference Reference
 Smear positive 0.36 (0.25–0.52) 0.00 0.52 (0.35–0.78) 0.00 0.47 (0.33–0.68)
 No smear performed 0.88 (0.50–1.54) 0.64 0.78 (0.43–1.40) 0.40 0.86 (0.49–1.51)
Table 5 Adjusted hazard ratios with  confidence intervals 
from a Cox model after multiple imputation for all deaths 
during  TB treatment according to  age group (<45  years 
vs. ≥45 years of age)
TB tuberculosis, ART antiretroviral treatment, TMP-SMX trimethoprim 
sulfamethoxazole 160/80 mg chemoprophylaxis, aHR adjusted hazard ratio, 
95 % CI 95 % confidence interval
<45 years of age ≥45 years of age
aHR (95 % CI) p value aHR (95 % CI) p value
Sex female 0.98 (0.83–1.16) 0.802 1.11 (0.86–1.44) 0.423
Anatomic site of TB
 Pulmonary Reference Reference
 Extra-pulmonary 1.16 (0.92–1.47) 0.213 1.20 (0.84–1.69) 0.313
 Both 1.52 (1.14–2.01) 0.004 1.21 (0.72–2.05) 0.473
Prior TB 1.10 (0.92–1.33) 0.299 1.31 (1.01–1.70) 0.042
HIV infected 3.16 (2.34–4.27) <0.001 1.18 (0.87–1.59) 0.282
TB smear result
 Smear negative Reference Reference
 Smear positive 0.99 (0.81–1.21) 0.904 0.76 (0.56–1.02) 0.068
 No smear  
performed
1.21 (0.94–1.56) 0.142 0.87 (0.57–1.31) 0.501
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proportion of TB patients have co-morbid illnesses such 
as hypertension (37 %) and diabetes (12 %) in this com-
munity [44]. If these co-morbid illnesses contribute to 
TB-related deaths, interventions would need to be imple-
mented at TB diagnosis to diagnose and treat them.
Conclusions
In a surveillance population of over 16,000 adults with 
active TB, several important predictors of death during 
TB treatment were recognized. In those not infected with 
HIV, the risk of death increased with advancing age but 
decreased with smear-positive disease. In those infected 
with HIV, the risk of death increased with advancing 
age and female gender but decreased with a higher CD4 
count and ART. In a region of high TB incidence and 
high HIV prevalence with scarce resources, stratifica-
tion at TB diagnosis by age, gender, HIV status and smear 
result would enable targeted interventions to reduce TB-
related deaths.
Methods
Study population
Khayelitsha is located in Cape Town, South Africa and 
is a high density (>7500 inhabitants/km2) predominantly 
black African township consisting of more than 500,000 
people [17]. From 2005 to 2007, annual TB case notifica-
tion rates in Khayelitsha ranged from 1200 to 1400 per 
100,000 people in the general population. TB patients in 
Khayelitsha are treated in 11 TB clinics administered by 
the City of Cape Town’s Health Department. According 
to national protocol, TB patients receive standardized 
TB treatment regimens using Directly Observed Therapy 
Short-course (DOTS) [18]. National guidelines at the time 
of our study recommended antiretroviral treatment (ART) 
for all TB patients with a CD4+ cell count less than 200 
cells/μL or a history of a WHO stage 4 illness [18]. Extra-
pulmonary TB—although a World Health Organization 
(WHO) stage 4 illness—was not an indication for ART 
unless the patient’s CD4+ count was less than 200 cells/
μL. First-line ART during our study was stavudine, lami-
vudine, and either nevirapine or efavirenz. Efavirenz was 
preferred for adults receiving rifampin-based TB treat-
ment. National guidelines also recommended daily tri-
methoprim-sulfamethoxazole (TMP-SMX, 160/800  mg) 
chemoprophylaxis [18]. Khayelitsha was one of the first 
townships in South Africa to integrate HIV and TB 
healthcare services. As a result, our previously described 
TB cohorts are characterized by high rates of voluntary 
counseling and testing of HIV status, as well as provision 
of TMP-SMX chemoprophylaxis (>95 %) [19–21].
Our study included all adult (>16 years of age) TB patients 
in Khayelitsha who initiated TB treatment from 1 January 
2007 to 31 December 2009 and were recorded in ETR.net 
Table 6 Adjusted hazard ratios with  confidence intervals 
from  a Cox model after  multiple imputation for  all HIV-
infected deaths during  TB treatment according to  age 
group (<45 years vs. ≥45 years of age)
TB tuberculosis, ART antiretroviral treatment, TMP-SMX trimethoprim 
sulfamethoxazole 160/80 mg chemoprophylaxis, aHR adjusted hazard ratio, 
95 % CI 95 % confidence interval
<45 years ≥45 years
aHR (95 % CI) p value aHR (95 % CI) p value
Sex female 1.10 (0.92–1.31) 0.310 1.44 (1.04–2.01) 0.030
Anatomic site of TB
 Pulmonary Reference Reference
 Extra-pulmo-
nary
1.14 (0.89–1.46) 0.273 1.05 (0.66–1.66) 0.838
 Both 1.33 (1.00–1.80) 0.052 1.09 (0.59 – 2.01) 0.775
Prior TB 1.13 (0.93–1.37) 0.234 1.39 (0.98–1.97) 0.066
TB smear result
 Smear negative Reference Reference
 Smear positive 1.08 (0.87–1.33) 0.471 0.94 (0.63–1.39) 0.741
 No smear 
performed
1.16 (0.89–1.52) 0.262 0.81 (0.48–1.39) 0.447
CD4 count
 <50 Reference Reference
 50–100 0.76 (0.57–1.02) 0.065 0.92 (0.54–1.59) 0.771
 100–200 0.51 (0.37–0.70) <0.001 0.62 (0.38–1.04) 0.068
 200–350 0.44 (0.33–0.58) <0.001 0.40 (0.23–0.70) 0.002
 350+ 0.23 (0.15–0.37) <0.001 0.29 (0.13–0.67) 0.005
TMP-SMX 
chemoprophy-
laxis
0.83 (0.54–1.27) 0.393 0.96 (0.30–3.04) 0.936
ART during TB 
treatment
0.67 (0.44–0.83) <0.001 0.44 (0.27–0.72) 0.001
Table 7 Adjusted hazard ratios with  confidence intervals 
from  a Cox model after  multiple imputation for  all HIV-
uninfected deaths during  TB treatment according to  age 
group (<45 years vs. ≥45 years of age)
TB tuberculosis, ART antiretroviral treatment, TMP-SMX trimethoprim 
sulfamethoxazole 160/80 mg chemoprophylaxis, aHR adjusted hazard ratio, 
95 % CI 95 % confidence interval
<45 years ≥45 years
aHR (95 % CI) p value aHR (95 % CI) p value
Sex female 0.84 (0.45–1.54) 0.565 0.82 (0.51–1.30) 0.391
Anatomic site of TB
 Pulmonary Reference Reference
 Extra-pulmonary 1.10 (0.45–2.67) 0.835 1.36 (0.76–2.44) 0.295
 Both 1.37 (0.32–5.09) 0.671 1.22 (0.38–3.93) 0.744
Prior TB 1.64 (0.85–3.17) 0.139 1.33 (0.85–2.07) 0.206
TB smear result
 Smear negative Reference Reference
 Smear positive 0.41 (0.19–0.90) 0.027 0.57 (0.35–0.93) 0.025
 No smear per-
formed
1.02 (0.33–3.18) 0.970 0.87 (0.42–1.77) 0.697
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(Electronic Tuberculosis Register). ETR.net is an electronic 
database that was designed in consultation with TB manag-
ers in South Africa and developed with support from the US 
President’s Emergency Plan for AIDS Relief (PEPFAR) [22]. 
ETR.net is used for TB/HIV surveillance, program moni-
toring and evaluation [22]. It provides standardized cohort 
reports including case finding, smear results, outcomes of 
treatment and HIV testing and services for TB patients [22]. 
ETR.net has been implemented in several countries includ-
ing South Africa, Guatemala, Mozambique, Namibia, Bot-
swana, Swaziland and Tanzania [22].
Study design
Variables obtained from the ETR.net database included 
age, gender, HIV status, TB smear result at TB diagnosis, 
history of prior TB, site of TB (pulmonary vs. extra-pul-
monary vs. both), outcome (dead, alive, lost to follow-up 
or transferred to another health district) and duration 
of follow-up. Among those infected with HIV, variables 
such as CD4 count, ART use during TB treatment, and 
TMP-SMX use during TB treatment were also recorded. 
In this study, we included all TB patients receiving TB 
treatment at one of the 11  TB clinics in Khayelitsha. A 
TB death was defined according to the WHO criteria, 
which is ‘any death during TB treatment, irrespective 
of cause’ [23]. Patients lost to follow-up and transferred 
out were censored at the time of their last visit. The 
Human Research Ethics Committee of the University of 
Cape Town and the Cape Town City Health Department 
approved this study.
Statistical methods
Patient characteristics (gender, age, TB site, TB his-
tory, TB smear, outcome) were summarized by HIV 
status using medians with interquartile ranges (IQR) or 
proportions. We also explored the effect of CD4 count, 
TMP-SMX chemoprophylaxis, and ART use on death 
in HIV-infected patients. Age and CD4 count were 
described as continuous variables and used as categori-
cal variables in modeling. On the basis of the assump-
tion that data were likely missing at random [24], we used 
multiple imputations by chained equations [25] to impute 
missing age [n = 1 (0.02 % of HIV uninfected data); n = 1 
(0.01 % of HIV infected data)], CD4 [n = 3946 (38.02 % 
of HIV infected data)], TMP-SMX chemoprophylaxis 
[n =  367 (3.54  % of HIV infected data)], and ART data 
for HIV-infected patients [n  =  1437 (13.85  % of HIV 
infected data)]. The multiple imputation models for the 
above variables included all measured variables as well 
as follow-up time. We used Stata’s implementation of the 
chained equation approach and used predictive mean 
matching to guarantee that imputed CD4 counts and age 
lie within the range of the observed data. All results of 
the statistical models relied on the imputed datasets and 
were combined by Rubin’s rules [24].
Cumulative mortality of patients was visualized using 
the Kaplan–Meier estimator. To identify risk factors for 
death, we used Cox proportional hazards models and 
reported hazard ratios and their respective 95  % con-
fidence intervals. All patients on TB treatment were 
considered and included in the model. We performed 
sub-analyses for both HIV positive and HIV negative 
populations. We also performed model selection using 
Akaike’s Information Criterion to obtain the most pre-
dictors of death [26].
Authors’ contributions
DJP and GM conceived the study; DJP, VA, RJW and GM designed the study; 
DJP and VA collected data for the study; DJP and MS analyzed the data; DJP 
drafted the initial manuscript; MS, RJW, VA and GM critically revised the manu-
script. All authors read and approved the final manuscript.
Author details
1 Department of Medicine, University of Cape Town, Anzio Road, Cape 
Town 7925, South Africa. 2 Critical Care Medicine Department, National 
Institutes of Health, 10 Center Drive, Bethesda, USA. 3 Centre for Infectious 
Disease Epidemiology and Research, University of Cape Town, Anzio Road, 
Cape Town 7925, South Africa. 4 Clinical Infectious Diseases Research Initiative, 
Institute of Infectious Diseases and Molecular Medicine, University of Cape 
Town, Cape Town, South Africa. 5 Department of Medicine, Imperial College, 
London W2 1PG, UK. 6 City Health, Cape Town, South Africa. 7 Division of Phar-
macology, Groote Schuur Hospital, Anzio Road, Cape Town 7925, South Africa. 
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 28 May 2015   Accepted: 25 September 2015
References
 1. WHO 2012. Global tuberculosis control. 2012. http://whqlibdoc.who.int/
publications/2011/9789241564380_eng.pdf. Accessed 1 Sep 2015.
 2. Van den Broek J, Mfi nanga S, Moshiro C, O’Brien R, Mugomela A, Lefi M. 
Impact of human immunodeficiency virus infection on the outcome of 
treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J 
Tuberc Lung Dis. 1998;2:547–52.
 3. Kang’ombe C, Harries AD, Banda H, et al. High mortality rates in tubercu-
losis patients in Zomba Hospital, Malawi, during 32 months of follow-up. 
Trans R Soc Trop Med Hyg. 2000;94:305–9.
 4. Zachariah R, Spielmann MP, Harries AD, Salaniponi FM. Moderate to 
severe malnutrition in patients with tuberculosis is a risk factor associated 
with early death. Trans R Soc Trop Med Hyg. 2002;96:291–4.
 5. Sacks LV, Pendle S. Factors related to in-hospital deaths in patients with 
tuberculosis. Arch Intern Med. 1998;158:1916–22.
 6. Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM. 
Factors associated with an increased case-fatality rate in HIV-infected and 
non-infected South African gold miners with pulmonary tuberculosis. Int 
J Tuberc Lung Dis. 2000;4:705–12.
 7. Connolly C, Davies GR, Wilkinson D. Impact of the human immunode-
ficiency virus epidemic on mortality among adults with tuberculosis in 
rural South Africa, 1991–1995. Int J Tuberc Lung Dis. 1998;2:919–25.
 8. Gustafson P, Gomes VF, Vieira CS, et al. Clinical predictors for death in 
HIV-positive and HIV-negative tuberculosis patients in Guinea-Bissau. 
Infection. 2007;35:69–80.
Page 9 of 9Pepper et al. AIDS Res Ther  (2015) 12:35 
 9. Harries AD, Nyangulu DS, Kangombe C, et al. Treatment outcome of an 
unselected cohort of tuberculosis patients in relation to human immu-
nodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop 
Med Hyg. 1998;92:343–7.
 10. Kelly PM, Cumming RG, Kaldor JM. HIV and tuberculosis in rural sub-
Saharan Africa: a cohort study with two year followup. Trans R Soc Trop 
Med Hyg. 1999;93:287–93.
 11. Cain KP, Anekthananon T, Burapat C. Causes of death in HIV-infected per-
sons who have tuberculosis, Thailand. Emerg Infect Dis. 2009;15:258–64.
 12. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immu-
nodefi ciency virus and the outcome of treatment for new and recurrent 
pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 
1999;159:733–40.
 13. Vasankari T, Holmstrom P, Ollgren J, Liippo K, Kokki M, Ruutu P. Risk factors 
for poor tuberculosis treatment outcome in Finland: a cohort study. BMC 
Public Health. 2007;7:291.
 14. Hargreaves NJ, Kadzakumanja O, Phiri S, et al. What causes smear-nega-
tive pulmonary tuberculosis in Malawi, an area of high HIV prevalence? 
Int J Tuberc Lung Dis. 2001;5:113–22.
 15. Barker RD, Nthangeni ME, Millard FJ. Is the distance a patient lives from 
hospital a risk factor for death from tuberculosis in rural South Africa? Int J 
Tuberc Lung Dis. 2002;6:98–103.
 16. de Valliere S, Barker RD. Poor performance status is associated with early 
death in patients with pulmonary tuberculosis. Trans R Soc Trop Med 
Hyg. 2006;100:681–6.
 17. Business Trust and dplg. Khayelitsha Nodal Economic Development 
Profile. 2007. http://www.btrust.org.za/index.php?id=148&tx_abdown-
loads_pi1[action]=getviewcatalog&tx_abdownloads_pi1[category_
uid]=26&tx_abdownloads_pi1[cid]=120&cHash=064d6b4433. Accessed 
1 Sep 2015.
 18. South African Department of Health. The South African National 
Tuberculosis Control Programme Practical Guidelines. 2004. http://www.
kznhealth.gov.za/chrp/documents/Guidelines/Guidelines%20National/
Tuberculosis/SA%20TB%20Guidelines%202004.pdf. Accessed 1 Sep 2015.
 19. Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, et al. Clinical 
deterioration during antituberculosis treatment in Africa: incidence, 
causes and risk factors. BMC Infect Dis. 2010;10:83.
 20. Pepper DJ, Marais S, Bhaijee F, Wilkinson RJ, De Azevedo V, et al. Barriers to 
initiation of antiretrovirals in HIV-infected patients receiving antitubercu-
losis treatment. PLoS One. 2011;6(5):e20077.
 21. Pepper DJ, Marais S, Bhaijee F, Wilkinson RJ, De Azevedo V, Meintjes G. 
Assessment at antiretroviral clinics during tb treatment reduces loss to 
follow-up among HIV-Infected patients. PLoS One. 2012;7(6):e37634.
 22. ETR.NET of South Africa. The Electronic Tuberculosis Register. 2010. http://
www.etrnet.info/Default.aspx. Accessed 1 Sep 2015.
 23. WHO 1994 World Health Organization. Global tuberculosis programme. 
A framework for effective tuberculosis control. WHO/TB/94.179. Geneva: 
WHO; 1994.
 24. Rubin D. Multiple imputation after 18+ years. J Am Stat Assoc. 
1996;91:473–89.
 25. White I, Royston P, Wood A. Multiple imputation using chained equations. 
Stat Med. 2011;30:377–99.
 26. Schomaker M, Heumann C. Model selection and model averaging after 
multiple imputation. Comput Stat Data Anal. 2014;71:758–70.
 27. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, 
Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L. 
Gender differences in survival among adult patients starting antiret-
roviral therapy in South Africa: a multicentre cohort study. PLoS Med. 
2012;9(9):e1001304.
 28. Abos-Hernandez R, Olle-Goig JE. Patients hospitalised in Bolivia with 
pulmonary tuberculosis: risk factors for dying. Int J Tuberc Lung Dis. 
2002;6:470–4.
 29. Duarte EC, Bierrenbach AL, Barbosa da Silva J Jr, Tauil PL, de Fatima 
Duarte E. Factors associated with deaths among pulmonary tuberculosis 
patients: a case-control study with secondary data. J Epidemiol Com-
munity Health. 2009;63:233–8.
 30. Baussano I, Pivetta E, Vizzini L, Abbona F, Bugiani M. Predicting tubercu-
losis treatment outcome in a low-incidence area. Int J Tuberc Lung Dis. 
2008;12:1441–8.
 31. Faustini A, Hall AJ, Mantovani J, Sangalli M, Perucci CA. Treatment out-
comes and relapses of pulmonary tuberculosis in Lazio, Italy, 1999–2001: 
a six-year follow-up study. Int J Infect Dis. 2008;12:611–21.
 32. Shen X, Deriemer K, Yuan Z, et al. Deaths among tuberculosis cases in 
Shanghai, China: who is at risk? BMC Infect Dis. 2009;9:95.
 33. Quy HT, Cobelens FG, Lan NT, Buu TN, Lambregts CS, Borgdorff MW. 
Treatment outcomes by drug resistance and HIV status among tuber-
culosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis. 
2006;10:45–51.
 34. Cole SR, Hernán MA, Margolick JB, Cohen MH, Robins JM. Marginal 
structural models for estimating the effect of highly active antiretroviral 
therapy initiation. Am J Epidemiol. 2005;162(5):471–8.
 35. WHO. TBHIV co-infection: summary of major studies and considerations 
for 2009 ART guidelines review. 2009. http://www.who.int/hiv/topics/
treatment/tbhiv_co-infection_summary_evidence.pdf. Accessed 1 Sep 
2015.
 36. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G. Clinical deteriora-
tion during antitubercular treatment at a district hospital in South Africa: 
the importance of drug resistance and AIDS defining illnesses. PLoS One. 
2009;4(2):e4520.
 37. Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, McIlleron H, De 
Azevedo V, Cox H, McDermid C, Sokhela S, Patel J, Meintjes G. Clinical 
deterioration during antituberculosis treatment in Africa: incidence, 
causes and risk factors. BMC Infect Dis. 2010;30(10):83.
 38. Zachariah R, Spielmann MP, Chinji C, Gomani P, Arendt V, Hargreaves NJ, 
Salaniponi FM, Harries AD. Voluntary counselling, HIV testing and adjunc-
tive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, 
Malawi. AIDS. 2003;17(7):1053–61.
 39. Mwaungulu FB, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyon-
goloka H, Harries AD, Glynn JR, Fine PE. Cotrimoxazole prophylaxis 
reduces mortality in human immunodeficiency virus-positive tuber-
culosis patients in Karonga District, Malawi. Bull World Health Organ. 
2004;82(5):354–63.
 40. Van Cutsem G, Ford N, Hildebrand K, Goemaere E, Mathee S, et al. Cor-
recting for mortality among patients lost to follow up on antiretroviral 
therapy in South Africa: a cohort analysis. PLoS One. 2011;6(2):e14684.
 41. Waitt CJ, Squire SB. A systematic review of risk factors for death in 
adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 
2011;5:871–85.
 42. Deretic V. Autophagy as an immune defense mechanism. Curr Opin 
Immunol. 2006;18(4):375–82.
 43. http://www.mrc.ac.za/bod/faqdeath.htm. What are the top causes of 
death in South Africa? Accessed 1 Sep 2015.
 44. Oni T, Youngblood E, Boulle A, McGrath N, Wilkinson RJ, Levitt NS. Patterns 
of HIV, TB, and non-communicable disease multi-morbidity in peri-urban 
South Africa—a cross sectional study. BMC Infect Dis. 2015;17(15):20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
